Login
Companies $CYTK
$52.61 -$0.56 (1.05%) After hours
CYTOKINETICS INC logo

CYTOKINETICS INC

cytokinetics.com

What Do They Do?

Sells MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy and develops muscle-directed medicines for cardiovascular and neuromuscular diseases.

How Do They Make Money?

Most revenue comes from partners’ upfront license fees, milestone payments tied to development, regulatory or commercial goals, and royalties on licensed-product sales; partners also reimburse research and development costs.

revenue
SegmentShareRevenue
License and Milestone Revenues
Licensed

90%
FY2022: 1.1%
Collaboration Revenues
9.9%
FY2022: 7.0%

Who Are Their Customers?

Cytokinetics targets cardiologists and disease-specific centers with its U.S. sales team; it has licensing arrangements with Sanofi in China and Bayer in Japan.

Do Revenues Turn Into Profits?

No. It lost $785M in FY2025.

Operating income, FY2025
−695% of revenue
▼ −14% (Loss) vs FY2024 (−$536.2M, −2903%)
Net income, FY2025
−892% of revenue
▼ −33% (Loss) vs FY2024 (−$589.5M, −3191%)
Free cash flow, FY2025
−607% of revenue
▼ −34% (Loss) vs FY2024 (−$399.8M, −2164%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +2356%
vs $1.9M in Q3 FY2025
Net income
▲ +38% (Loss)
vs −$306.2M in Q3 FY2025
License and Milestone Revenues share of revenue vs 0.0% in Q3 FY2025

Growing. Revenue grew 25% in 4 years, from $70.4M in FY2021 to $88M in FY2025, about 6% a year.

From research to sales Cytokinetics has moved from developing investigational medicines toward selling MYQORZO as its first approved medicine, while continuing drug development.

Broader research approaches Earlier research centered on small molecules that modulate muscle contractility; the latest report adds targeted protein degraders, oligonucleotides and tissue-targeting approaches.

Revenue over time
License and Milestone Revenues Collaboration Revenues Realization of Revenue Participation Right Purchase Agreement
$100M$50M$0

Who Do They Compete With?

Competes with Bristol Myers Squibb, Edgewise Therapeutics, Lexicon, Tenaya, Braveheart Bio (Hengrui), Novartis, Merck &, Bayer, AstraZeneca, and Kardigan

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support